- Conditions
- Posterior Fossa Ependymal Tumor
- Interventions
- Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 985
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Interventions
- Metformin XR, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LCQ908A, Placebo, Sitagliptin, metformin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 693 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 48
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Metformin, Rosiglitazone, Lifestyle Program
- Drug · Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Type 2 Diabetes
- Interventions
- AZD1656, Glucagon
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy
- Interventions
- Metformin HCl
- Drug
- Lead sponsor
- Torrent Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Polycystic Ovary Syndrome, Disorder of Glucose Regulation
- Interventions
- Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Exercise Capacity, Metformin
- Interventions
- Metformin Hydrochloride, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- Copanlisib (Aliqopa, BAY80-6946), Metformin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy Adults
- Interventions
- KP-001, Metformin, Midazolam, Clarithromycin
- Drug
- Lead sponsor
- Kaken Pharmaceutical
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy
- Interventions
- Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR Tablets 500 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Lung Cancer
- Interventions
- Metformin, Placebo, Stereotactic body Radiotherapy (SBRT)
- Drug · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Melanoma
- Interventions
- Pembrolizumab Injection [Keytruda], Metformin
- Drug
- Lead sponsor
- Yana Najjar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus Type 2 in Obese
- Interventions
- standard of care in general clinical practice
- Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
- Interventions
- Not listed
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
- Conditions
- Diabetes, Diabetes Mellitus Type 2
- Interventions
- Liraglutide, Metformin, Placebo, NNC0090-2746
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 20
- States / cities
- Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- BMS-820132, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Miami, Florida
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Metformin, Pharmacological Study, Sapanisertib
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- PreDiabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Body Weight, Body Weight Changes
- Interventions
- DiRECT, Usual care (UC)
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ipragliflozin, Placebo, Metformin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Coral Gables, Florida • Hialeah, Florida + 2 more
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
- Interventions
- metformin hydrochloride, placebo, Chemotherapy
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more